CG-0255 is under clinical development by Shanghai CureGene Pharmaceutical and currently in Phase II for Ischemic Stroke. According to GlobalData, Phase II drugs for Ischemic Stroke have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CG-0255’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CG-0255 overview
CG-0255 is under development for the treatment of acute coronary syndrome, myocardial infarction, percutaneous coronary intervention, ischemic stroke and unspecified cardiovascular disorders. The drug candidate is administered through parenteral, intravenous and oral routes. It acts by targeting P2Y Purinoceptor 12.
Shanghai CureGene Pharmaceutical overview
Shanghai CureGene Pharmaceutical is engaged in research, development and sale of novel drugs for the treatment of cerebrovascular, cardiovascular and anti-viral diseases. The company is headquartered in Shanghai City, Shanghai, China.
For a complete picture of CG-0255’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
